New Perspectives on Antimicrobial Agents: Imipenem-Relebactam-Reference-Cited by-同舟云学术

New Perspectives on Antimicrobial Agents: Imipenem-Relebactam

Published:2022-07-19 Issue:7 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

O’Donnell J. Nicholas¹^ORCID,Lodise Thomas P.¹^ORCID

Affiliation:

1. Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, New York, USA

Abstract

Imipenem (IMI)/cilastatin/relebactam (REL) (I/R) is a novel β-lactam/β-lactamase inhibitor combination with expanded microbiologic activity against carbapenem-resistant non- Morganellaceae Enterobacterales (CR-NME) and difficult-to-treat (DTR) Pseudomonas aeruginosa . Relebactam, a bicyclic diazabicyclooctane, has no direct antimicrobial activity but provides reliable inhibition of many Ambler class A and class C enzymes.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00256-22

Reference90 articles.

1. Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®

2. In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa

3. Susceptibility to Imipenem/Relebactam of Pseudomonas aeruginosa and Acinetobacter baumannii Isolates from Chinese Intra-Abdominal, Respiratory and Urinary Tract Infections: SMART 2015 to 2018

4. Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae

5. Anonymous. 2019. RECARBRIO™ (imipenem cilastatin and relebactam) for injection for intravenous use. Merck Sharp & Dohme LLC Rahway NJ USA. https://www.merck.com/product/usa/pi_circulars/r/recarbrio/recarbrio_pi.pdf. Accessed on February 1 2022.

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Agents Targeting the Bacterial Cell Wall as Tools to Combat Gram-Positive Pathogens;Molecules;2024-08-27

2. On the assessment of the role of new antibiotics in pharmacotherapy algorithms for complicated intra-abdominal infections (literature review);Journal of Volgograd State Medical University;2024-08-05

3. Size-dependent antibacterial efficacy of silver nanoparticles from a green synthesis method: Effects of extract quantity and origin;Journal of the Taiwan Institute of Chemical Engineers;2024-08

4. Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam;Microbiology Spectrum;2024-06-04

5. Finding value in novel antibiotics: How can infectious diseases adopt incremental cost-effectiveness to improve new antibiotic utilization?;Diagnostic Microbiology and Infectious Disease;2024-06